Medicare has changed its stance on GLP-1 drugs like Wegovy, moving into 2026. While it is known for its weight loss effects, Medicare Part D plans will finally be able to cover the drug under a new medical indication. Because the Food and Drug Administration (FDA) has officially approved Wegovy for reducing the risk of heart attack and stroke in people with cardiovascular disease, it is now covered by Medicare.
This shift opens the door for many seniors who were previously blocked by federal law from accessing the medication when it was prescribed solely for obesity. But coverage is not automatic, and the rules are more complicated than many headlines suggest. Here is what the new policy actually means for you.
